TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has symptomatic osteoarthritis of the knee diagnosed using clinical and radiographic evidence as well as ACR criteria with symptom duration of at least 6 months.~* Subject requires therapeutic dose of an NSAID, COX-2 NSAID, and/or paracetamol/acetaminophen for osteoarthritis pain of the index knee and has taken that medication at least 5 days per week for the last 4 weeks prior to the screening visit (Visit 1).~Exclusion Criteria:~* Subject is not able to withdraw NSAIDs, COX-2 NSAIDs and/or paracetamol~* Subject is taking analgesic other than NSAIDs COX-2 NSAIDs and/or paracetamol~* Subject is planning to begin or stop treatment with glucosamine and/or chondroitin during the trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): lacosamide (LCM)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tezosentan in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~1. Signed informed consent prior to initiation of any study-mandated procedure~2. Male and female patients 18 years of age or older~3. Patients with PAH according to one of the following subgroups of the Dana Point Classification Group 1:~   * Idiopathic, or~  * Heritable, or~  * Associated with connective tissue disease~4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of study mandated procedures):~   * Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and~  * Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and~  * Pulmonary capillary wedge pressure ≤ 15 mmHg~5. Modified NYHA functional class II-III~6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days prior to Visit 1.~Exclusion Criteria :~1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion No. 3~2. Patients with sitting SBP \< 100 mmHg~3. Patients with sitting DBP \< 60 mmHg~4. Patients with body weight \< 50 kg (110 lbs)~5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or alkaline phosphatase \> 3 times upper limit)~6. Patients with clinically significant chronic renal insufficiency (serum creatinine \>2.5mg/dL / 221 µmol/L)~7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)~8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost and beraprost) within 28 days of Visit 1~9. Patients who have received any investigational drugs within 28 days of Visit 1~10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit 1~11. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study~12. Life expectancy less than 12 months~13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum test at Screening and urine test on Visit 1 and 2) or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after last administration of study drug~14. Known hypersensitivity to any of the excipients of the drug formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Placebo at visit 1, tezosentan at visit 2
- 2 (Type: EXPERIMENTAL): Tezosentan at visit 1, placebo at visit 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written Informed Consent provided by patient~2. MM, with the following conditions:~(CLOSED) \*For patients in the Vanguard cohort\*~1. Treatment naïve disease with BM clinically indicated~\*For patients in the RRMM cohort\*~1. Relapsed/refractory disease with BM samples clinically indicated~2. Within 4-weeks prior to initiation of 2nd-line or later therapy~3. Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)~Exclusion Criteria:~1. Unable or unwilling to provide informed consent~2. Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)~3. Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study~4. Prior exposure to CAR-T therapy~5. Prior allogeneic stem cell transplant~6. Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy~7. Has received any Ab therapy within 4 weeks prior to BM biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vanguard (Type: None): (CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
- Relapsed/Refractory MM (Type: None): BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of ppROM With Erythromycin vs. Azithromycin Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal age ≥ 18 years and \<50 years~* Pregnant women between the gestational age 23 6/7 and 32 6/7 weeks~* Singleton pregnancy~* Preterm premature rupture of membranes, determined clinically~* Cervical dilation visually ≤ 5cm on sterile speculum exam.~* Planned delivery at John Sealy Hospital (JSH)~Exclusion Criteria:~* Intrauterine fetal demise (no fetal heart beat identified and documented by two physicians)~* Any contraindication to expectant management (e.g. fetal compromise, chorioamnionitis, placental abruption)~* Cervical cerclage in place~* Placenta previa or other known placental anomalies~* Contraindication to any of the antibiotics used (allergy to macrolides).~* Enrolled in another trial that may affect outcome.~* Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention.~* No prenatal care (less than 2 prenatal visits)~* Non-resident subject who is unlikely to be followed-up after delivery~* Any fetal congenital anomaly.~* Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal~* Significant renal disease defined as serum creatinine known to be \>2.0 mg/dl or on dialysis.~* Active congestive heart failure (EF\<45%) or pulmonary edema.~* Immunosuppressed subjects: i.e., taking systemic immunosuppressants or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4\<200, or other.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
- Erythromycin (Type: ACTIVE_COMPARATOR): Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Born in San Francis Designated District Hospital of Ifakara~Exclusion Criteria:~* Obvious severe congenital malformation such as: spina bifida, hydrocephalus or anencepahlus~* Twins~* Birth weight \< 1,5 kg~* Clinical signs of cerebral asphyxia~* Clinical signs of neonatal or congenital infection~* Mother unreliable (deaf, mentally handicapped)

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 1 Day
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA Bladder Injection Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men, 18 years of age or older~* Self-reported failed conservative care of behavioral modifications and/or oral medications for the treatment of OAB~* Average urinary frequency of \> 8 voids per day as recorded on initial 3-day voiding diary~* Self-reported bladder symptoms \> 3 months~* Discontinued antimuscarinics/beta-3 agonists for \> 2 weeks prior to study enrollment. May restart antimuscarinics/beta-3 agonists if indicated \> 6 weeks after Botox injections.~* Capable of giving informed consent~* Capable and willing to follow all study-related procedures~* Previous OnabotulinumtoxinA injection at least three months prior to study enrollment.~Exclusion Criteria:~* Pregnant or planning to become pregnant during study duration~* Diagnosis of neurogenic bladder with the exception of highly functioning stroke patients~* If a patient has had a previous neuromodulation device placed, it will have to be turned off for 2 weeks for a washout period and remain off throughout the study~* Previous non-responders to onabotulinumtoxinA (BTX) therapy~* Patient cannot be receiving percutaneous nerve stimulation (PTNS) therapy. If patient is receiving PTNS, they need to stop for 1 month prior to entering the study.~* Refusal to self-catheterize or have indwelling catheter in the event of urinary retention~* Use of investigational drug/device therapy within past 4 weeks~* Participation in any clinical investigation involving or impacting gynecologic, urinary or renal function within past 4 weeks~* Current or past history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation~* Pelvic radiation treatment~* Known hypersensitivity to OnabotulinumtoxinA.~* Previous infection at OnabotulinumtoxinA injection site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3 Injection Sites (Type: EXPERIMENTAL): OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
- 10 Injection Sites (Type: EXPERIMENTAL): OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children that are admitted to the paediatric ward of the Isala Klinieken in Zwolle for the first time with acute dyspnea and wheezing~* Age 1 - 4 years~* Child and parents must understand the Dutch language well~* Informed consent~Exclusion Criteria:~* Previous use of medication different than short-acting β2-agonists before hospital admission~* Proven RSV bronchiolitis~* Crackles during auscultation of the lungs (suggestive for RSV bronchiolitis)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Beclomethasone (Type: ACTIVE_COMPARATOR): Inhaled corticosteroids
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Even-Up to Minimize Secondary Site Pain For Ankle Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-operative Treatment of Ankle Fracture~* CAM boot as treatment for injury~* Weight bearing ad lib~Exclusion Criteria:~* Pregnancy~* Non-English speaking~* Recent surgery for lower extremity or back~* Recent other injury to lower extremity or back~* Restricted weight bearing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Standard CAM boot treatment without Even-Up device.
- Study (Type: EXPERIMENTAL): CAM boot treatment with Even-Up for contralateral extremity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 10 obese men (BMI\>30), aged 18 to 55, with glomerular hyperfiltration (creatinine clearance\>130 ml/min) will be included in the study.~Exclusion Criteria:~* Any of the following conditions:~  * Heart failure~ * Known allergy to furosemide, inulin or amino-hippurate~ * Pharmacologic treatment for hypertension, cardiac disease, diabetes mellitus~ * Treatment with corticosteroids or NSAID

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Furosemide, obesity, glomerular hyperfiltration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any adult (≥ 18 years of age) who has ESRD and a prevalent or incident tunneled hemodialysis catheter and expected to continue hemodialysis for 3 months will be eligible for enrollment.~Exclusion Criteria:~* The following patients will be excluded from study entry:~  1. patient is unable (and no guardian or legal representative is available) or unwilling to provide informed consent and~ 2. patient is allergic to NAC, tigecycline, minocycline, or heparin.~The following patients will be excluded from randomization:~1. patient has evidence of a complicated bacteremia such as endocarditis, septic thrombophlebitis, septic emboli, osteomyelitis, deep seated abscess, or hypotension requiring use of vasopressors,~2. patient has evidence of an exit site infection around the catheter such as a pus pocket, purulent drainage, or erythema,~3. patient is pregnant or will become pregnant,~4. the infection is due to an organism that is resistant to tigecycline such as Candida or Pseudomonas species.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NAC/Tigecycline/Heparin combination lock solution (Type: EXPERIMENTAL): A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
- Standard anticoagulant (heparin or citrate) (Type: PLACEBO_COMPARATOR): Standard anticoagulant (heparin or citrate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Participant with AS who participated and completed 12-week treatment in study DRI11073-NCT01061723.~Exclusion criteria:~* Adverse event(s) having lead to treatment discontinuation in the DRI11073 study;~* Event or laboratory abnormality observed at the last treatment visit of DRI11073 study that would have adversely affected participation of the participant in this study as per investigator judgment.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarilumab (Type: EXPERIMENTAL): Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pasireotide Therapy in Patients With Nelson's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* To be verified at Visit one and confirmed at Visit two~* Male or female patients aged 18-80 years~* Signs and symptoms consistent with Nelson's Syndrome~* Biochemistry consistent with Nelsons syndrome: failure to suppress plasma ACTH to less than 200 pg/ml at 2 hours following morning dose of hydrocortisone~* Negative pregnancy test where applicable~Exclusion Criteria:~* Received any prior or current treatment with a pasireotide or other somatostatin analogue.~* Requires surgery for recent significant deterioration in visual fields or other neurological signs related to tumour mass.~* Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or persistent ALT, AST, alkaline phosphates 2X\> upper limit of normal, or total bilirubin 1.5X\> upper limit of normal.~* Patients with symptomatic cholelithiasis~* Abnormal clinical laboratory values considered by the Investigator to be clinically significant and which could affect the interpretation of the study results~* QTcF interval as measured by ECG \>480msecs~* Any current or prior medical condition that may, in the opinion of the Investigator, interfere with the conduct of the study or evaluation of the results.~* Female patients who are pregnant or lactating, or of childbearing potential and not practising a medically acceptable method of birth control. Medically acceptable methods include including the oral contraceptive pill, intrauterine devices, mechanical methods (e.g. vaginal diaphragm, vaginal sponge, or condom with permicidal jelly).~* History of alcohol or drug abuse in the sixmonth period prior to Visit 1, or who plan to take an investigational~* History of alcohol or drug abuse in the six month period prior to Visit 1, or who plan to take an investigational drug for another study during this study.~* History of noncompliance to medical regimes or who are considered potentially unreliable.~* Pituitary radiotherapy within the last 1 year prior to study entry.~* Unable to complete the entire study for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pasireotide (Type: EXPERIMENTAL): 4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues